{
    "medicine_id": "4b44bf62850706c9e1bc4e17a58476d22dcb9e39",
    "platform_id": "DB12688",
    "metadata": {
        "name": "Lumoxiti 1 mg 1mL Injection powder lyophilized for solution",
        "composition": "1 mg 1mL Moxetumomab Pasudotox",
        "clinical_particulars": {
            "therapeutic_indications": "MxP is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia HCL who received at least two prior systemic therapies including treatment with a purine nucleoside analog The use of this drug is not recommended in patients with severe renal impairment CrCl 29 ml min L4568 HCL is an uncommon type of lymphocytic leukemia that starts in B cells or B lymphocytes It is characterized by an accumulation of abnormal B lymphocytes HCL is called hairy as it produces hair like projections in the surface of the cancer cells A usual symptom in people having HCL is the presence of splenomegaly and less often hepatomegaly A38877",
            "contraindications": {
                "disease": "No studies have been performed regarding the carcinogenic potential and or effect on fertility of MxP It has been observed that the administration of MxP in a dose 3 times the recommended can produce the degeneration of heart tissue and a dose 10 times the recommended there are reports of gliosis axonal degeneration in the spinal cord and body tremors FDA label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Compared with its predecessor MxP is even 50 fold more active on lymphoma cell lines and leukemic cells In phase I clinical trial MxP showed no dose limiting toxicity and the overall response rate was of 79 From pediatric patients with acute lymphoblastic leukemia the complete response was observed in 12 individuals which is a result that has never been seen before A38880 In an open label clinical trial MxP showed a complete response defined as the maintenance of hematologic remission of more than 180 days in 30 of the patients and 75 of the patients achieved at least partial response L4568 Hence the phase III clinical trial met the primary endpoint of durable complete response L4572",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Moxetumomab Pasudotox"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Moxetumomab Pasudotox"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Moxetumomab Pasudotox"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Moxetumomab Pasudotox"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}